WO2007018124A1 - コラーゲン産生増強剤とその用途 - Google Patents
コラーゲン産生増強剤とその用途 Download PDFInfo
- Publication number
- WO2007018124A1 WO2007018124A1 PCT/JP2006/315410 JP2006315410W WO2007018124A1 WO 2007018124 A1 WO2007018124 A1 WO 2007018124A1 JP 2006315410 W JP2006315410 W JP 2006315410W WO 2007018124 A1 WO2007018124 A1 WO 2007018124A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trehalose
- collagen production
- mass
- parts
- skin
- Prior art date
Links
- 230000037319 collagen production Effects 0.000 title claims abstract description 152
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 55
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 100
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 93
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims description 63
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 59
- 239000003623 enhancer Substances 0.000 claims description 49
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 40
- 239000002211 L-ascorbic acid Substances 0.000 claims description 30
- 229960005070 ascorbic acid Drugs 0.000 claims description 30
- 150000008064 anhydrides Chemical class 0.000 claims description 15
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 241000238557 Decapoda Species 0.000 claims description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- 239000001177 diphosphate Substances 0.000 claims description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 3
- 235000011180 diphosphates Nutrition 0.000 claims description 3
- 150000004712 monophosphates Chemical class 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- 235000011178 triphosphate Nutrition 0.000 claims description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 abstract description 41
- 108010035532 Collagen Proteins 0.000 abstract description 41
- 229920001436 collagen Polymers 0.000 abstract description 41
- 235000000346 sugar Nutrition 0.000 abstract description 22
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 81
- 239000000047 product Substances 0.000 description 63
- 230000000694 effects Effects 0.000 description 44
- 239000002609 medium Substances 0.000 description 42
- 150000001720 carbohydrates Chemical class 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 32
- -1 α, α trehalose saccharide derivatives Chemical class 0.000 description 32
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 31
- 229920001287 Chondroitin sulfate Polymers 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 31
- 229940059329 chondroitin sulfate Drugs 0.000 description 31
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 30
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 29
- 235000014633 carbohydrates Nutrition 0.000 description 27
- 239000002537 cosmetic Substances 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 26
- 239000006210 lotion Substances 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 239000006188 syrup Substances 0.000 description 22
- 235000020357 syrup Nutrition 0.000 description 22
- 235000015872 dietary supplement Nutrition 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 19
- 229920002674 hyaluronan Polymers 0.000 description 19
- 229960003160 hyaluronic acid Drugs 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 239000013078 crystal Substances 0.000 description 18
- 229920002385 Sodium hyaluronate Polymers 0.000 description 17
- 235000013305 food Nutrition 0.000 description 17
- 229940010747 sodium hyaluronate Drugs 0.000 description 17
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 230000007423 decrease Effects 0.000 description 13
- 230000036541 health Effects 0.000 description 13
- 239000008213 purified water Substances 0.000 description 12
- 230000037303 wrinkles Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000032683 aging Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 230000009759 skin aging Effects 0.000 description 11
- 239000012085 test solution Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 150000000996 L-ascorbic acids Chemical class 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000003796 beauty Effects 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 235000015110 jellies Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000008274 jelly Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 5
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 5
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229940025878 hesperidin Drugs 0.000 description 5
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 5
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000004373 Pullulan Substances 0.000 description 4
- 229920001218 Pullulan Polymers 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019423 pullulan Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 229920002305 Schizophyllan Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940097275 indigo Drugs 0.000 description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- 125000000647 trehalose group Chemical group 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 240000000731 Fagus sylvatica Species 0.000 description 2
- 235000010099 Fagus sylvatica Nutrition 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940072106 hydroxystearate Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical class OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- HFWHTGSLDKKCMD-UHFFFAOYSA-N 2,2-bis(octanoyloxymethyl)butyl octanoate Chemical compound CCCCCCCC(=O)OCC(CC)(COC(=O)CCCCCCC)COC(=O)CCCCCCC HFWHTGSLDKKCMD-UHFFFAOYSA-N 0.000 description 1
- YTDFTWJWBQPUPJ-UHFFFAOYSA-N 2-methylhexyl 3-(4-methoxyphenyl)prop-2-enoate Chemical compound CCCCC(C)COC(=O)C=CC1=CC=C(OC)C=C1 YTDFTWJWBQPUPJ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000347485 Silurus glanis Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940062353 acid jelly Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- HDTRYLNUVZCQOY-NCFXGAEVSA-N beta,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-NCFXGAEVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000000162 organ preservation solution Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003625 trehaloses Chemical class 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/34—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds characterised by carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a novel collagen production enhancer and a composition for enhancing collagen production, specifically, collagen production comprising a, ⁇ -trehalose and / or a carbohydrate derivative of ⁇ , ⁇ -trehalose.
- the present invention relates to an enhancer and a yarn composition for enhancing collagen production containing the collagen production enhancer.
- a decrease in the amount of collagen produced in fibroblasts is a decrease in the body's defense function, which is one of the important functions of the skin, not only by advancing skin aging.
- Collagen such as collagen causes weakening of the tissues and organs in the body where the structure is maintained, which causes health problems.
- collagen is a protein, it is difficult to be absorbed directly into the body if it is taken orally or applied to the skin surface.Furthermore, it cannot enhance the collagen-producing activity of fibroblasts. It cannot be the fundamental prevention or treatment of skin aging.
- collagen which is a major component of tissues and organs, including dermis, bones, and blood vessels, is aimed at preventing aging and maintaining and improving health of tissues such as skin, blood vessels, and bones.
- a collagen production enhancer containing a derivative of L-corsic acid and royal jelly has been proposed. (See JP 2003-171290). It has also been reported that carbohydrates such as glucose enhance collagen production (eg, Han DC, et al., J. Nanoreb, American Society of Nef the American Society of Nepnrology), 3 ⁇ 43 ⁇ 410, brother
- ⁇ , ⁇ -trehalose is a disaccharide in which two molecules of glucose are bonded to each other through a reducing group, and the saccharide derivatives thereof are 3 or more having the ex, a trehalose structure in the molecule.
- These non-reducing saccharides have the ability of glucose, and these saccharides can be used as substitutes for sucrose in the fields of food, cosmetics, quasi-drugs, and pharmaceuticals.
- the demand for foods and drinks and skin external preparations that utilize properties such as prevention, lipid degradation, and protein denaturation is growing rapidly.
- a, ⁇ -trehalose and carbohydrate derivatives of ⁇ , ⁇ -trehalose are known substances, and for example, the same applicant has filed a number of patents regarding methods for producing these carbohydrates and their uses (for example, JP-A-7-143876, JP-A-7-213283, JP-A-2000-228980, and International Publication WO 2004/056216).
- JP-A-7-143876, JP-A-7-213283, JP-A-2000-228980, and International Publication WO 2004/056216 for example, JP-A-7-143876, JP-A-7-213283, JP-A-2000-228980, and International Publication WO 2004/056216.
- a, ⁇ -trehalose has been disclosed for use as an excipient for a collagen production enhancer (see, for example, JP-A-2003-171290), these documents include a, ⁇ -trehalose.
- An object of the present invention is to provide a means for effectively enhancing collagen production by L-lascorbic acids.
- the present invention is based on the finding that ⁇ , a-trehalose and Z or ⁇ , ⁇ trehalose saccharide derivatives have an effect of remarkably enhancing collagen production by L ascorbic acids in animals including humans. Is based.
- ⁇ , ⁇ trehalose and saccharide derivatives of ⁇ or ⁇ , ⁇ trehalose are stable, safe and have no serious side effects, and can be used for a long time. It can be used simply and comfortably to prevent skin aging, maintain and enhance beauty and health, and strengthen bones and blood vessels.
- the ⁇ , ⁇ -trehalose and ⁇ or ⁇ , ⁇ trehalose carbohydrate derivatives used in the present invention exert an action of enhancing collagen production by L-ascorbic acid in animals including humans. Either can be used advantageously in the present invention. Therefore, the collagen production enhancer of the present invention only needs to contain an effective amount as a whole of one or more of these a, a trehalose and a, a-trehalose carbohydrate derivatives. .
- ⁇ , ⁇ -trehalose and ⁇ , ⁇ trehalose saccharide derivatives used in the present invention can be prepared by various methods such as fermentation, enzyme, synthesis, and syrup and mass kit containing these Amorphous powder, dense crystal powder, crystal and the like can be advantageously used.
- These ⁇ , ⁇ trehalose and ⁇ , a trehalose saccharide derivatives are not necessarily highly purified and may be partially separated from other carbohydrates that coexist in the preparation process. Purified or highly refined or made Even if the reducing sugars coexisting in the production process are hydrogenated and converted to sugar alcohols, other appropriate components that do not substantially interfere with the collagen production-enhancing effect of L-ascorbic acid in mammals including humans.
- the present invention is not related to the preparation of ⁇ , ⁇ -trehalose and its derivatives, and therefore will not be described in detail.
- JP-A-7-143876 Non-reducing saccharide-forming enzyme and trehalose-free enzyme disclosed in JP-A-7-213283, JP-A-2000-228980, International Publication WO 2004Z056216, etc. are allowed to act on partial starch hydrolysates Is preferred.
- a, ⁇ -trehalose can be obtained in high yield from starch, which is an inexpensive material, with ⁇ , ⁇ -trehalose-containing sugar.
- a trehalose powder containing 98% by mass or more of hydrous crystalline trehalose in terms of solids (Hayashibara Shoji Co., Ltd.)
- a sale and product name "Trehha” a sale and product name "Trehha”
- the saccharide containing a saccharide derivative of a, a-trehalose include, for example, a maltosyl a, a trehalose in an amount of 50% by mass or more in terms of anhydride, and other saccharide derivatives of ⁇ , ⁇ -trehalose.
- syrup Commercially available from Hayashibara Shoji Co., Ltd., trade name “Hello Dettas” containing about 7% by mass of anhydride in terms of anhydride, and hydrogenated to convert coexisting reducing sugars into sugar alcohols.
- Syrup containing ⁇ -maltosyl a, a-trehalose in an amount of 50% by weight or more in terms of anhydride and other (X, a saccharide derivative of trehalose in an amount of about 10% by weight in terms of anhydride (Hayashibara Biochemical Co., Ltd. There are research sales and product names "Tornare”).
- the carbohydrate derivative of a, a-trehalose used in the present invention is not particularly limited as long as it can enhance collagen production by L-corcorbic acid.
- any one or two or more saccharides selected from non-reducing oligosaccharides having a trehalose structure in the molecule and having three or more glucose forces may be used. More specifically, it means that at least one of a, a trehalose molecule is bonded to any one selected from mono-glucose, di-glucose, tri-glucose and tetra-glucose force.
- carbohydrate derivatives of a, a trehalose, —darcosyl a, a Carbohydrates with a trehalose structure at the end of the molecule, such as renorose, ⁇ -manoletocinole a, a trenorose, a manoletotriosinore a, a trehalose and a maltotetraosyl, a trehalose, It can be advantageously used in the present invention where the effect of enhancing collagen production by acids is strong.
- a maltosyl a, a trehalose disclosed in International Publication WO 2004Z056216 and the like as a main component, and in addition, a gunolecosinole a, a-trenosucrose, a manoletotriosinore a, a— Carbohydrate containing one or two or more selected from trenorose and other a-glycosyl a-glucose forces is desirable.
- a-maltosyl a, a-trehalose is contained in an amount of about 5% by mass or more, preferably about 10% by mass or more, more preferably about 30% by mass or more in terms of anhydride, based on the total carbohydrates. Carbohydrates are desired.
- the collagen production enhancer of the present invention includes glucose, fructose, dalcosamine, ratatose, sucrose, a, ⁇ -trehalose, ⁇ , ⁇ -trehalose, ratatosucrose, within a range that does not interfere with the collagen production enhancing action.
- Cyclodextrins such as maltooligosaccharides, syrups, and cyclodextrins published in the same applicant's international publication WO 02Z10361, etc.
- High-sweetness sweeteners such as cyclic saccharides such as cyclic tetrasaccharides, sugar alcohols such as erythritol, mannitol, sorbitol, xylitol, maltitol, and reduced starch syrup, aspartame, stevia extract, sucralose, and acesulfame K , Pullulan, carrageenan, mucopolysaccharides such as chondroitin sulfate and their salts, natural gums, chitin, chitosan, synthetic high molecular weight polymers such as carboxymethylcellulose, thickeners such as collagen, gelatin, etc. More than seeds can be added.
- the collagen production enhancer of the present invention includes those other than a, a trehalose and a sugar derivative of a, ⁇ -trehalose, for example, disclosed in JP-A-10-203952.
- components having an effect of enhancing collagen production other than ⁇ , ⁇ trehalose and ⁇ , a-trehalose saccharide derivatives such as extracts from the buds of the beech genus Beech can be added as necessary.
- minerals such as deep ocean water, oyster shell calcium, emulsifiers, fragrances, spices, pigments such as vitamin B, vitamin B,
- Vitamins such as vitamins, vitamins such as derivatives of these vitamins, amino acids, CoQ 10 (Coenzyme Q 10), adenosine and derivatives thereof, monophosphate, diphosphate or triphosphate It can also be advantageously carried out to contain one or more components such as these bases.
- these bases such as mucopolysaccharides such as chondroitin sulfate, CoQ 10 (Coenzyme Q 10), adenosine and its derivatives, and their bases such as monophosphate, diphosphate or triphosphate are used together, a, a trehalose and Z Alternatively, it is possible to further enhance the collagen production enhancing action of a carbohydrate derivative of ⁇ , ⁇ trehalose.
- the selection criteria for these components are usually appropriately selected according to the needs of each application field of the collagen production enhancer of the present invention.
- L-ascorbic acid as used in the present invention means L-ascorbic acid and its derivatives, and induces collagen production of fibroblasts as it is or by being decomposed or modified by an enzyme or the like. It means a substance that can exert its action. Specifically, L-ascorbic acid glycosides such as L-ascorbic acid, L-ascorbic acid 2-darcoside, L-ascorbic acid glycosylated derivatives, L-ascorbic acid phosphate esters and sulfates There are these salts.
- L-ascorbic acid is present in an amount necessary for collagen production by fibroblasts, so it is not necessary to add L-ascorbic acids to the collagen production enhancer of the present invention.
- the standard of the amount of L-ascorbic acid used may be appropriately selected in accordance with each application field of the collagen production enhancer of the present invention, as the amount required for collagen production in animals including humans.
- the method for using the collagen production enhancer of the present invention will be described taking humans as an example.
- the collagen production enhancer of the present invention can be used orally or parenterally. Also exerts an effect of enhancing collagen production.
- the collagen production enhancer of the present invention is effective for enhancing collagen production in both cases of oral and parenteral use because of the above-described action.
- gavage stomach, enteral, etc.
- food or liquid syrup, powder, granule, tablet, capsule, etc., or skin Ophthalmic solution, injection solution, infusion solution, peritoneal cavity and thoracic cavity perfusion solution, organ / wound * eye * nasal cavity / burn, inflamed area, etc.
- peritoneal dialysis fluid, tissue or organ preservation solution, etc. collagen production at the target site will be enhanced, tissue and organ strengthening and wounds will be burned. It can also be used advantageously.
- the topical skin preparation as used in the present invention is any cosmetic product as long as the composition containing ⁇ , ⁇ -trehalose and wrinkle or a carbohydrate derivative of ⁇ , ⁇ -trehalose is in direct contact with the skin. Also includes quasi-drugs, miscellaneous goods such as detergents that can only be obtained from pharmaceuticals.
- the collagen production enhancer of the present invention has an active ingredient even when administered to animals including humans by oral, transcutaneous, or injection (including perfusion such as intraperitoneal) via a misplaced route. Because it is rapidly absorbed into the body and enhances collagen production by L-scorbic acid in fibroblasts present in the dermis, tissues, bones, organs, etc., when animals including humans ingest the collagen production enhancer, Collagen production is steadily enhanced, such as aging associated with aging, dialysis, inflammation-related diseases and tissue damage caused by surgery, and skin damaged by factors such as ultraviolet rays.
- a-trehalose and / or carbohydrate derivatives of a, a-trehalose are continuously enhanced in collagen production by L-ascorbic acids, and the skin Strengthens the dermis and keratinized layer to enhance the body's defense capabilities and suppresses / improves rough skin, so it is damaged by factors such as aging with age and ultraviolet rays and harmful microorganisms.
- Cosmetics applied to skin including scalp, quickly recovering the decrease in collagen production ability of the skin, giving the skin tension and moisture, removing koi ⁇ ⁇ , removing the rough skin and elasticity of the skin Use as In some cases, it is effective for prevention of skin diseases due to the above-mentioned effects, improvement of therapeutic effects on the diseases, and hair growth.
- the collagen production enhancer of the present invention and Z or a composition containing the same are applied directly to the skin as cosmetics, etc., if necessary, for example, in International Publication WO 01Z60388 by the same applicant, etc.
- penetration into the skin may be promoted.
- the collagen production enhancer of the present invention can also be used as a suppressor for the generation of shrimp, a hair growth agent, a tissue strengthening agent, and the like.
- the collagen production enhancer of the present invention can be easily used by animals including humans, and can also be used for maintaining and promoting health.
- tonics, health foods, health supplements, special foods It can also be used in the form of health functional foods, cosmetics, quasi-drugs, pharmaceuticals, feed, feed, pet food, miscellaneous goods, etc.
- the intake or dose of the collagen production enhancer of the present invention varies depending on the type, age, sex, etc. of animals and pets including humans, ⁇ trehalose and Z or ex, a in terms of anhydride
- a carbohydrate derivative of trehalose is usually administered in an amount of 0. OOlg to 2 g, preferably 0. Olg to lg orally (including tube administration) or parenterally other than transdermally, per kg of body weight.
- the dose may be taken once or several times a day, or may be taken every day or at intervals of 1 day or more depending on the effect.
- ⁇ , ⁇ -trehalose and ⁇ or ⁇ , ⁇ -trehalose saccharide derivatives are usually contained in an amount of 0.1% by mass or more, preferably 1% by mass or more in terms of anhydride.
- a trehalose used in the collagen production enhancer The saccharide derivative is 0.1% by mass to 20% by mass, preferably 1% by mass to 20% by mass in the total amount of the external preparation for skin in terms of anhydride, and 2% for obtaining a stable effect. % To 20% by weight is especially desirable. Divide once or several times a day, depending on the effect, spray or apply to the skin at intervals of one day or more. It is sufficient to make contact by the method.
- ⁇ trehalose and Z or ⁇ , ⁇ treno, saccharide sugar derivatives added to the skin external preparation, unless it is not preferred due to the physical properties or feeling of use of the external preparation for skin.
- water-soluble substances such as sodium polyacrylate, sodium polyglutamate, scleroglucan, tines seeds, pullulan, etc.
- Thickeners such as polysaccharides and the ability to use ethanol together, butylene glycol and glycerol may be blended in a mass ratio of 1:20 to 20: 1.
- the collagen production enhancer of the present invention is useful by itself, but can also be advantageously used in the form of a composition formed by blending with other components.
- a composition containing the collagen production enhancer of the present invention a, a trehalose according to an appropriate composition selected according to the target animal, its intake method or administration method, etc.
- a Trehalose carbohydrate derivative and can be used in any of the fields of foods and beverages, cosmetics, quasi drugs, pharmaceuticals, feeds, feeds, pet foods as shown above 1
- the seeds or two or more ingredients are mixed according to the purpose based on their individual contents, and the a, a-trehalose and / or a, a trehalose carbohydrate derivative is contained. Prepare the composition and shape it into the desired shape if necessary.
- Preparation of the collagen production enhancer of the present invention or a composition containing the same can be carried out by applying each component to an appropriate process up to the raw material step force product stage or an existing product, for example, Dilution, Concentration, Drying, Filtration, Centrifugation, Mixing, Kneading, Dissolving, Melting, Dispersing, Suspending, Emulsifying, Soaking, Spreading, Applying, Coating, Spraying, Injection, Crystallization, Solid, Reversed micelle
- Dilution, Concentration, Drying, Filtration, Centrifugation, Mixing, Kneading, Dissolving, Melting, Dispersing, Suspending, Emulsifying, Soaking, Spreading, Applying, Coating, Spraying, Injection, Crystallization, Solid, Reversed micelle One or two or more of these methods can be used in appropriate combination.
- compositions of the present invention include the above-mentioned or other individual uses of the composition of the present invention. Commonly used in the field, such as water, alcohol, starch, protein, amino acid, fiber, sugar, lipid, fatty acid, vitamin, mineral, flavoring, coloring, sweetener, seasoning, spice, preservative , Antioxidants, emulsifiers, surfactants, powders and the like.
- the collagen production enhancer of the present invention or a composition containing the same can be used for the purpose of enhancing collagen production, indicating that collagen production can be enhanced.
- Desirable forms of the external preparation for skin include, for example, lotions, emulsions, creams, solids, powders, jelly, mousse, packs, face masks, films as disclosed in International Publication WO 2004Z056216.
- Such as basic cosmetics, cleaning cosmetics, bath cosmetics, oral cosmetics, tanning / sunscreen cosmetics, makeup cosmetics, hair cosmetics (hair growth agents, hair restorers, etc.) and kitchen detergents Goods that directly affect the skin are listed.
- Examples of pharmaceuticals include intradermal, subcutaneous and intravascular injections, intraperitoneal perfusate 'washing solution, dialysate such as peritoneal dialysis, trauma cleaning solution' antiseptic solution, eye drops, nasal drops, topical preparations, etc. be able to.
- ice cream that is used to enhance collagen production
- ice candy such as ice candy and sherbet
- syrup such as ice honey, butter cream, custard cream, flower paste, Peanut paste, spread and paste such as fruit paste, chocolate, jellies, candy, gummy jelly, caramel, chewing gum, pudding, baked confectionery such as spun cream, sponge cake, jam, marmalade, syrup pickles, confectionery Processed fruits such as processed fruits or vegetables, manju, uirou, ann, mutton, water sheep candy, castella, candy balls, rice crackers, and other Japanese confectionery, rice cakes, fertilizer, cooked rice, prepared dishes, dried food, retort food, frozen food, Soy sauce, powdered soy sauce, miso, powdered taste , Mayonnaise, dressing, eating vinegar, Sanbaizu, mirin, table sugar, and seasonings, such as coffee sugar like it is.
- the collagen production enhancer of the present invention is usually 0.01% by mass to 20% by mass, desirably, 0.1 to 10% by mass is contained.
- D MEM medium 10% (v / v) fetal bovine serum and antibiotics in Dulbecco's MEM medium
- D MEM medium L-ascorbic acid 2-dalcoside (sales of Hayashibara Biochemicals, Inc.) , Reagent grade)
- AA-2GJ L-ascorbic acid 2-dalcoside
- ⁇ , ⁇ ⁇ trehalose sales grade, sold by Hayashibara Biochemicals Co., Ltd.
- the final concentration of AA-2G is 50
- a test solution was prepared by dissolving so that the final concentration of ⁇ , a, ⁇ trehalose was 7.5 mg / mU 15 mgZml or 30 mgZml.
- NHDF cells subcultured using D MEM medium are collected, resuspended in D—MEM medium, seeded in a 96-well microphone mouthplate with 2.5 X 10 4 cells Z200 / z lZ well 24 Incubate for hours. Thereafter, the culture medium was removed by suction, and 200 / z lZ well of any of the test liquids was added, followed by culturing for 5 days.
- As a control either 200 ml of D-MEM medium, D-MEM medium containing 30 mg / ml of a, a-trehalose, or 50 ⁇ AA-2G containing D-MEM medium was added. The culture was performed for a day.
- the culture medium is removed by suction, 1 mg acetic acid containing lmg / ml pepsin is added to each well, 50 / z lZ uel carlo, and the collagen attached to the cell surface is solubilized by shaking for 4 hours.
- the amount of accumulated collagen is determined using the Sircol collagen quantification kit (Biocolor
- AA-2G In D-MEM medium, add AA-2G and hydrated crystals ⁇ , a trehalose
- the final concentration of AA-2G is 50 ⁇ , ⁇ , ⁇ trehalose or maltose, either of which are sold by the Institute of Physical and Chemical Research, reagent grade) or hydrous crystal maltose (Hayashibara Biochemical Laboratories Co., Ltd., reagent grade).
- the test solution was prepared by dissolving to a concentration of 0.6 mgZml, 1.7 mg / ml, 5. OmgZml or 15. OmgZml.
- the NHDF cell culture and the method for quantifying the amount of collagen production were performed in the same manner as in Experiment 1.
- the culture supernatant of NHDF cells was collected, and the amount of collagen released into the supernatant was also measured using a silicon collagen quantification kit.
- 50 M AA-2G-containing D-MEM medium was used as a control.
- the experiment was carried out using 3 wells for each of the control and test solutions, and the average was obtained as the collagen production.
- the results indicate that the amount of collagen produced in the cell surface, in the culture supernatant, or in the total amount of these collagens is brought to the cell surface of NHDF cells when using 50 ⁇ ⁇ —2G-containing D—MEM medium.
- Table 2 shows the relative value of the total collagen production in the culture supernatant or in the culture supernatant.
- D-MEM medium AA-2G, water-containing crystal ⁇ , a trehalose (sales grade, sold by Hayashibara Biochemical Laboratories, Inc.), a maltosyl a, a-trehalose (manufactured by Hayashibara Biochemical Laboratories, purity) 98% or more), syrup containing ⁇ , ⁇ trehalose and carbohydrate derivatives (trade name “Hello Dettas”, sold by Hayashibara Corporation, approximately 53% of OC maltosyl ⁇ , a trehalose in terms of anhydride, other ⁇ , a) Any carbohydrate that contains about 5% of the total sugar derivatives of trehalose and a solid content of about 75%), and that the final concentration of AA-2G is M and the final concentration of carbohydrate is 15.
- the test solution was prepared by dissolving. Also, as a control, saccharides containing hydrated crystals a, a trehalose, a maltosyl ⁇ , ⁇ trehalose, or a saccharide saccharide containing a, ⁇ trehalose in a D-MEM medium with a final concentration of 15. OmgZml A test solution was prepared so as to be dissolved. A medium supplemented with syrup containing a carbohydrate derivative of ex, ⁇ -trehalose was prepared as 15. Omg / ml as a carbohydrate derivative of ⁇ , ⁇ -trehalose contained therein.
- D-MEM medium add AA-2G and hydrated crystals ⁇ , a trehalose Physiological Laboratories, reagent grade), a maltosyl a, a-trehalose (manufactured by Hayashibara Biochemical Laboratories Co., Ltd., purity 98% or more) or ⁇ , a-trehalose containing sugar derivatives Sales and trade name “Hello Dettas”) were dissolved so that the final concentration of AA-2G was 50 M and the final concentration of carbohydrate was 15. OmgZml.
- test solutions were prepared by dissolving hyaluronic acid in 1 mgZml, chondroitin sulfate in 1 mgZml, or hyaluronic acid and chondroitin sulfate in 0.5 mgZml each.
- the medium containing ex, ⁇ -trehalose saccharide derivative-containing syrup contains the a, a-trehalose contained in this medium.
- the sugar derivative was prepared to be 15. Omg / ml.
- the amount of collagen produced by NHDF cells when cultured in a medium supplemented with any of the three sugars, hyanorelonic acid and chondroitin sulfate was 344, 276 and 256, respectively.
- hyaluronic acid or chondroitin sulfate has an action of further enhancing collagen production by AA-2G by ⁇ , ⁇ -trehalose and its carbohydrate derivatives.
- hyaluronic acid and chondroitin sulfate are used in combination, either one is added.
- ⁇ a syrup containing this as a sugar derivative of ⁇ -trehalose (trade name “Tornale”, sold by Hayashibara Biochemical Laboratories, Inc., in terms of anhydride (X maltosyl ⁇ , a-trehalose is approximately 53%, other ⁇ , a- trehalose containing a total of about 5% saccharide derivative (solid content concentration: about 75%) An amount of lotion was prepared.
- each saccharide shown in Table 5 is shown in terms of anhydride.
- carbohydrate derivative-containing syrup of a, ⁇ -trehalose was added so that the carbohydrate derivative of a, ⁇ -trehalose had the blending ratio shown in Table 5.
- Skin lotion of any combination formula shown in Table 5 was used on the face 3 times daily for 4 months with 11 women suffering from skin wrinkles, koji wrinkles and looseness compared to before use. Skin condition was assessed by self-report. Evaluation is about changes in the skin wrinkles, folds and looseness of the skin, there is tension on the skin, the depth of the ridges becomes shallower (the number is less), the tension is on the skin, The number of shatters with shallow depth was reduced (effective), but the skin slackness was improved, but the depth and number of shrimp were not changed (slightly effective), no change Table 5 shows the number of subjects who made each evaluation.
- the basic prescription lotion contains sodium hyaluronate and / or chondroitin sulfate and 2 parts by weight of a, a monotrehalose or ⁇
- a -trehalose saccharide derivative is used compared to In addition, a strong improvement effect on skin slack and shiyakoji was observed.
- This sodium hyaluronate and Z or chondroitin sulfate can enhance the skin loosening of ex, a trehalose or ⁇ , ⁇ -trehalose saccharide derivatives and the improvement effect of coconut koji by using sodium hyaluronate or chondroitin sulfate alone. It was confirmed that the combination of both was stronger than the combination.
- the basic formula lotion or the lotion to which sodium hyaluronate and sputum or chondroitin sulfate were added in the amounts shown in Table 5, these lotions were evaluated as effective or effective. Subject was impressed.
- each saccharide shown in Table 6 is shown in terms of water free. Further, a syrup containing a carbohydrate derivative of a , a -trehalose was added so as to have a compounding ratio shown in Table 6 of Table a, a-trehalose. The same lotion of this combination was used on the face 3 times a day for 3 months with 11 women suffering from skin wrinkles, koi wrinkles and slack as in Experiment 5, and the same as in Experiment 5. Table 6 shows the results of evaluating the effect of the method on skin wrinkles, koji wrinkles and looseness.
- a, a trehalose or a carbohydrate derivative of a, hi-hitrehalose, 0.1 part by weight of hyaluronic acid, 0.1 part by weight of chondroitin sulfate are added to the basic prescription lotion.
- the makeup water supplemented with AMP and Z or CoQlO was used.
- oc, ⁇ trehalose or ⁇ , ⁇ trehalose carbohydrate attractant, 0.1 parts by weight of sodium hyaluronate and 0.1 parts by weight of chondroitin sulfate were used. Compared to the case, a strong improvement effect on skin sag and shrimp was observed.
- Is a composition comprising a, a-trehalose or a carbohydrate derivative thereof and a composition strength a, a-rehalose, or any combination selected from sodium hyaluronate, chondroitin sulfate, AMP and CoQIO. It can be more advantageously used as an enhancer of collagen production by L-ascorbic acid, an agent for improving skin loosening, an inhibitor, or an agent for improving scabs, compared to a composition comprising the carbohydrate derivative. Tells the story.
- This product is an easily usable and highly effective collagen production enhancer that exhibits an effect of enhancing collagen production, moisturizes the skin, and is effective in preventing skin aging.
- this product shows a good taste due to moderate acidity, it is labeled as being used for enhancing collagen production, and it remains as a health supplement for enhancing collagen production. It can also be taken freely, or dissolved in water or other beverages. Furthermore, it can be freely mixed with special-purpose foods, health functional foods, cosmetics, quasi drugs, pharmaceuticals, feeds, feeds, pet foods, miscellaneous goods, and the like to impart collagen enhancing action to these.
- Tablets were prepared by tableting the product in lg. This product can be sold with indication that it enhances collagen production.
- Hydrous crystals ⁇ , ⁇ -trehalose Hydrous crystals ⁇ , ⁇ -trehalose (Hayashibara Corporation
- This product can be used as a health supplement that can be used for enhancing collagen production with a label indicating that it is used for enhancing collagen production.
- this product has an excellent effect on normalization of skin tissue and prevention of aging, and is suitable as a health supplement for daily use that shows good taste due to mild sweetness and moderate acidity. is there.
- This product is used as a composition for oral ingestion or tube administration not only for humans but also for animals such as livestock and pets, or for farmed animals such as fish, shrimp and force, etc. This can be used advantageously.
- sucrose fatty acid ester was added to the health supplement for enhancing collagen production so as to be 1% by mass, and the tablet was formed into tablets of about 300 mg per tablet.
- This product is a health supplement that enhances collagen production that exhibits a long-lasting collagen production enhancing effect, is stable for a long period of time, is convenient to carry, and is easy to ingest.
- this product can be used as a health supplement that can be used to enhance collagen production with a label indicating that it is used to enhance collagen production.
- the following ingredients were mixed uniformly in the following composition to prepare a powdered health supplement for enhancing collagen production. After the preparation, it was confirmed that the collagen production enhancer showed a collagen production enhancing action stably.
- Hydrous crystals ⁇ , ⁇ trehalose Hydrous crystals ⁇ , ⁇ trehalose (Hayashibara Corporation
- This product can be used as a health supplement that can be used for enhancing collagen production with a label indicating that it is used for enhancing collagen production.
- this product has an excellent effect on normalization of skin tissue and prevention of aging, and is suitable as a health supplement for daily use that shows good taste due to mild sweetness and moderate acidity. is there.
- Example 4
- a blend comprising the above blend composition was prepared. 25 parts by mass of this blend was uniformly dispersed and dissolved in 150 parts by mass of purified water, and 200 g each was enclosed in a brown glass bottle.
- This product is a health supplement drink that can be used for enhancing collagen production with a label indicating that it is used for enhancing collagen production.
- this product is a delicious beverage with a reduced amount of off-flavor and off-flavours derived from these ingredients, such as beauty and health. It can be used advantageously for the purpose.
- This product can be advantageously used as a composition for oral intake or tube administration for animals such as domestic animals and pets as well as humans.
- this product contains transglycosylated hesperidin, it is optional to indicate that it can be used to reduce blood lipids such as blood lipids and blood cholesterol.
- Powder maltitol 25 parts by mass Hydrous crystals ⁇ , ⁇ trehalose (Hayashibara Corporation
- these ingredients were stirred and mixed until homogeneous, and tableted by 0.5 g by a conventional method to prepare tablets.
- This product is a health supplement that can be used for enhancing collagen production with a label indicating that it is used for enhancing collagen production.
- this product contains darcosamine, chondroitin sulfate, and hyaluronic acid in addition to maintaining the collagen production enhancing action, so it is particularly excellent in bone tissue strengthening and joint strengthening.
- This product is a delicious health food that suppresses odors and odors derived from dalcosamine, chondroitin sulfate, and hyaluronic acid, and can be advantageously used for beauty and health purposes.
- this product can be advantageously used as a composition for oral ingestion or tube administration not only for humans but also for animals such as livestock and pets.
- Hydrous crystals ⁇ , ⁇ trehalose Hydrous crystals ⁇ , ⁇ trehalose (Hayashibara Corporation
- Glucose transfer rutin (Toyo Seika Co., Ltd., trade name "A G rutin P") 0.5 parts by mass
- the total amount was 100 parts by mass, and these components were stirred and mixed until homogeneous, and tableted by 0.5 g by a conventional method to prepare tablets.
- This product is a health supplement that can be used for enhancing collagen production with an indication that it is used for enhancing collagen production.
- this product contains hyaluronic acid in addition to sustaining the collagen production enhancing action, it particularly improves skin slackness, bone tissue strengthening, joint strengthening and joint pain. Excellent effect.
- This product is a delicious health food that can be used advantageously for beauty and health purposes.
- This product can be advantageously used as a composition for oral ingestion or tube administration not only for humans but also for animals such as livestock and pets.
- ⁇ -Trehalose sugar derivative-containing syrup (trade name “Hello Dettas” sold by Hayashibara Shoji Co., Ltd.) Add 5 parts by mass, mix overnight, freeze in freezer to obtain ice cream .
- This product can be used for enhancing collagen production, with an indication that it is used for enhancing collagen production.
- This product is an ice cream that moisturizes skin and prevents skin aging.
- Hydrous crystals ⁇ , ⁇ trehalose Hydrous crystals ⁇ , ⁇ trehalose (Hayashibara Corporation
- This product can be used for enhancing collagen production with an indication that it is used for enhancing collagen production.
- This product is a fruit jelly that shows moderate sweetness and smooth texture, prevents skin aging, and helps maintain and enhance beauty and health.
- This product can be used for enhancing collagen production with an indication that it is used for enhancing collagen production.
- This product is a tea beverage that prevents skin aging and helps maintain and enhance beauty and health.
- this product contains transglycosyl hesperidin It is also optional to indicate that it is used to reduce blood lipids such as blood neutral fat and blood cholesterol.
- formulation B Addition and mixing of formulation B according to a conventional method to formulation A described below, and after cooling to 30 ° C or lower, adjust the pH to be weakly acidic with potassium hydroxide, emulsify with a homogenizer, A skin external cream was produced.
- Soybean extract 0.5 parts by weight
- Aloe vera extract 0.5 parts by weight
- Licorice extract 0.5 parts by weight Purified water 62.4 parts by mass
- This cream may be further made into a weakly alkaline cream by adding potassium hydroxide as necessary.
- This product enhances and sustains collagen production in the skin, so that the looseness of the skin is improved, it is also effective against mildew, and has an excellent anti-aging effect. Moreover, since this product exhibits excellent moisture retention, it is useful as a basic cosmetic product.
- a lotion was prepared by a conventional method based on the formulation shown below.
- Adenosine monophosphate 0.5 parts by mass
- This lotion enhances and sustains collagen production in the skin, so it keeps the skin fresh, improves looseness, is effective against mulberry, and has an excellent anti-aging effect.
- Indigo grass water extract and dipotassium glycyrrhizinate show excellent anti-inflammatory action and whitening effect, and are useful as basic cosmetics and whitening cosmetics.
- Formulation A described below is dissolved in purified water to prepare an aqueous solution.
- Weighing and dissolving Formulation B, heating and dissolving it, adding Formulation C to this to form a gel, adding it to the aqueous solution of Formulation A, stirring until uniform, and applying lotion by conventional methods Was prepared.
- Screotium gum solution (1% ⁇ ⁇ glucan-containing solution) 3 parts by mass
- This product is a micro emulsion that contains a small amount of oil in a stable manner. Since it has the effect of enhancing and sustaining production, it maintains the freshness of the skin, improves the looseness, is effective for scouring, and has an excellent anti-aging effect. In addition, since this product contains scleroglucan, a water-soluble polysaccharide, the feeling of use of a topical skin preparation containing a carbohydrate derivative of ⁇ -trehalose is further improved and is durable. It gives a moist feeling and is excellent for moisturizing students.
- Example 13 The formulation described below is weighed, warmed and dissolved.
- the mixture B was weighed, heated and dissolved, and emulsified, stirred and cooled to room temperature using a homomixer, and an essence was prepared by a conventional method.
- Soybean lysophospholipid solution (25%) 1 part by mass
- Sorbitan monostearate 0.5 parts by weight
- This product has the effect of enhancing and sustaining the collagen production of the skin, so it keeps the skin fresh, improves the looseness, is effective against mulberry pods, and prevents aging Are better.
- this product contains water-soluble polysaccharides such as scleroglucan and tines seed extract, the feeling of using a topical skin preparation containing a carbohydrate derivative of a, ⁇ -trehalose is further improved. It has a long lasting moist feeling and is excellent for moisturizing students.
- this product uses a saccharide derivative of a, ⁇ -trehalose, which reduces surface tension and is finer than the conventional D-phase preparation using polyhydric alcohol. It is characterized by a stable emulsified droplet form, and can be used by blending it into a gel, lotion, cream, bathing agent or the like.
- a pack agent was prepared by a conventional method using the formulation described below.
- This product enhances and sustains the production of collagen in the skin, so it keeps the skin fresh, improves looseness, is effective against rustling, and has excellent anti-aging and moisturizing effects.
- this product is excellent in feeling of use, has a strong strength, and can be easily wiped off and peeled off from the skin after being semi-dried or dried, and has an excellent cleaning effect on the skin surface and pores.
- Toothpaste was prepared by a conventional method based on the following compositional formulation. Since this product contains supple, citrate rehalose and its carbohydrate derivatives, it can enhance the collagen production of gingival cells, so it can suppress gingival loss due to aging and gingivitis, It is a toothpaste that has a clean feeling after washing and has a clean feeling after washing, and can also remove plaque cleanly.
- carbohydrate derivatives of a, a trehalose and ⁇ , a trehalose effectively suppress the production of adherent insoluble glucan from sucrose by glucanotransferase of caries fungus (Streptococcus mutans). Therefore, it has excellent anti-corrosion properties.
- Titanium oxide 0.4 parts by mass
- a Syrup containing maltosyl a, a-trehalose manufactured by Hayashibara Biochemical Laboratories Co., Ltd., purity 98.5%, solid content 75%) 6g, L-corsic acid 2-dalcoside (manufactured by Hayashibara Biochemical Laboratories, Inc., purity 99. 5% J 2. lg, sodium chloride
- This product is a peritoneal dialysis solution that can enhance the production of collagen in the organs and walls of the abdominal cavity and strengthen the tissues and organs in the abdominal cavity.
- this product has excellent storage stability and biocompatibility, such as dialysis fluid for hemodialysis, lavage fluid for wounds and organs, perfusion fluid for intraperitoneal cavity and thoracic cavity, and preservation fluid for tissues and organs. Can also be used.
- the present invention provides a collagen production enhancer comprising ⁇ , ⁇ trehalose and ⁇ or a carbohydrate derivative of ⁇ , ⁇ trehalose, which is remarkable for animals including humans. This is based on a completely unique finding that it effectively enhances collagen production by L-ascorbic acids.
- the collagen production enhancer can be used to prevent skin aging, enhance the beauty of animals, including humans, who are not concerned about serious side effects. Maintaining capacity and health 'can be used for improvement.
- collagen production enhancer of the present invention having the above-described features can be combined with other ingredients to produce foods, beverages, special-purpose foods, health functional foods, cosmetics, quasi drugs, pharmaceuticals, It can also be advantageously used as various compositions such as feed, feed, pet food and sundries.
- the present invention is an invention that exhibits such remarkable effects and is a truly significant invention that contributes greatly to the world.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/063,563 US20090110671A1 (en) | 2005-08-11 | 2006-08-03 | Agent for enhanching the production of collagen and it's use |
EP06782270A EP1932530A4 (en) | 2005-08-11 | 2006-08-03 | MEANS FOR IMPROVING COLLAGEN PRODUCTION AND ITS USE |
JP2007529534A JP5106109B2 (ja) | 2005-08-11 | 2006-08-03 | コラーゲン産生増強剤とその用途 |
KR1020087001705A KR101342192B1 (ko) | 2005-08-11 | 2008-01-22 | 콜라겐 산생 증강제와 그 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-232679 | 2005-08-11 | ||
JP2005232679 | 2005-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007018124A1 true WO2007018124A1 (ja) | 2007-02-15 |
Family
ID=37727309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/315410 WO2007018124A1 (ja) | 2005-08-11 | 2006-08-03 | コラーゲン産生増強剤とその用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090110671A1 (ja) |
EP (1) | EP1932530A4 (ja) |
JP (1) | JP5106109B2 (ja) |
KR (1) | KR101342192B1 (ja) |
CN (2) | CN101232891A (ja) |
WO (1) | WO2007018124A1 (ja) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110171286A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
JPWO2009116450A1 (ja) * | 2008-03-17 | 2011-07-21 | 株式会社林原生物化学研究所 | エラスターゼ活性阻害剤 |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
KR20140072008A (ko) * | 2011-06-03 | 2014-06-12 | 알러간, 인코포레이티드 | 항산화제를 포함하는 피부 충전제 조성물 |
US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US8946192B2 (en) * | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9062130B2 (en) | 2003-04-10 | 2015-06-23 | Allergan Industrie Sas | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
US9089517B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
JP2015151379A (ja) * | 2014-02-18 | 2015-08-24 | 株式会社ノエビア | 水性クレンジング料 |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
WO2020226147A1 (ja) * | 2019-05-07 | 2020-11-12 | 株式会社林原 | ゲル状皮膚外用組成物 |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US11260015B2 (en) | 2015-02-09 | 2022-03-01 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
KR20230143550A (ko) * | 2022-04-05 | 2023-10-12 | (주)뉴트리 | 저장 안정성이 향상된 콜라겐 조성물 및 이의 제조방법 |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008147867A2 (en) * | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Cross-linked collagen and uses thereof |
US8318695B2 (en) * | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US8394784B2 (en) * | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
KR101372757B1 (ko) * | 2009-09-14 | 2014-03-10 | 닛뽕소다 가부시키가이샤 | 항식물 바이러스제 |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
KR101781556B1 (ko) * | 2010-11-30 | 2017-09-27 | (주)아모레퍼시픽 | 홍조류 추출물을 함유하는 항노화용 화장료 조성물 |
CN103501757B (zh) * | 2011-02-01 | 2016-01-20 | 株式会社林原 | 皮肤外用剂 |
US20140315828A1 (en) | 2013-04-22 | 2014-10-23 | Allergan, Inc. | Cross-linked silk-hyaluronic acid compositions |
CA3239805A1 (en) | 2013-05-07 | 2014-11-13 | Seelos Therapeutics, Inc. | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
US9084720B2 (en) | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
EP3160440B1 (fr) * | 2014-06-30 | 2021-10-27 | NUTRICOS Technologies | Produits de combinaison et compositions cosmétiques pour lutter contre les désordres de la peau et son vieillissement affectant les kératinocytes et/ou les fibroblastes et le derme |
FR3022779B1 (fr) * | 2014-06-30 | 2018-03-30 | Nutricos Technologies | Produits de combinaison et compositions cosmetiques pour lutter contre les desordres de la peau et son vieillissement affectant les keratinocytes |
DE102014223570A1 (de) * | 2014-11-19 | 2016-05-19 | Beiersdorf Ag | Zubereitungen mit einem Gehalt an Ascorbinsäure, Ubidecarenon und Phosphationen zur verbesserten Hautkonturierung bzw. gegen Cellulite |
EP3439491A1 (en) * | 2015-12-13 | 2019-02-13 | Verburgh, Kris | Methods and compositions to slow down aging in cells and organisms |
US10300169B2 (en) | 2016-08-24 | 2019-05-28 | Allergan, Inc. | Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation |
CN109010130A (zh) * | 2018-09-12 | 2018-12-18 | 华南理工大学 | 一种聚氧化乙烯护肤用面膜载体基材及其制备方法 |
WO2021085293A1 (ja) * | 2019-10-30 | 2021-05-06 | 東洋精糖株式会社 | セルライト改善用皮膚外用剤、およびセルライト改善方法 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07143876A (ja) | 1992-12-28 | 1995-06-06 | Hayashibara Biochem Lab Inc | 非還元性糖質生成酵素とその製造方法並びに用途 |
JPH07213283A (ja) | 1993-06-03 | 1995-08-15 | Hayashibara Biochem Lab Inc | トレハロース遊離酵素とその製造方法並びに用途 |
JPH10203952A (ja) | 1997-01-17 | 1998-08-04 | Shiseido Co Ltd | コラーゲン産生促進剤 |
JP2000159656A (ja) * | 1998-12-01 | 2000-06-13 | Taiyo Kagaku Co Ltd | コラーゲン合成促進剤 |
JP2000228980A (ja) | 1998-09-11 | 2000-08-22 | Hayashibara Biochem Lab Inc | 非還元性糖質生成酵素及びトレハロース遊離酵素ならびに該酵素を用いる糖質の製造方法 |
JP2001048789A (ja) * | 1999-08-09 | 2001-02-20 | Yaizu Suisankagaku Industry Co Ltd | 美肌促進剤及び美容健康食品 |
WO2001060388A1 (fr) | 2000-02-15 | 2001-08-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Activateur de cellules |
WO2002010361A1 (fr) | 2000-08-01 | 2002-02-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Synthase d'$g(a)-isomaltosylglucosaccharide, procede de preparation et utilisation associes |
JP2003171290A (ja) | 2001-09-27 | 2003-06-17 | Hayashibara Biochem Lab Inc | コラーゲン産生増強剤の製造方法とその用途 |
JP2004107243A (ja) * | 2002-09-17 | 2004-04-08 | Fancl Corp | シワ及び/又はたるみ改善用キット |
JP2004174880A (ja) | 2002-11-27 | 2004-06-24 | Toppan Printing Co Ltd | 潜像を有する画像形成体およびその顕像化方法 |
WO2004056216A1 (ja) | 2002-12-19 | 2004-07-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 組成物における水分の変動を抑制する方法とその用途 |
WO2004071472A1 (ja) * | 2003-02-13 | 2004-08-26 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α,α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤 |
JP2005095148A (ja) | 2003-08-28 | 2005-04-14 | Hayashibara Biochem Lab Inc | 環状マルトシルマルトース及び環状マルトシルマルトース生成酵素とそれらの製造方法並びに用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2865320B2 (ja) * | 1989-08-07 | 1999-03-08 | 株式会社資生堂 | 固型化粧料組成物 |
JPH06279294A (ja) * | 1993-03-24 | 1994-10-04 | Lion Corp | コラーゲン合成促進剤 |
JP2002528400A (ja) * | 1998-10-26 | 2002-09-03 | ユニバーシティー オブ マサチューセッツ | アデノシンまたはアデノシン類似体を用いた皮膚の治療 |
JP2001302435A (ja) * | 2000-04-28 | 2001-10-31 | Hayashibara Biochem Lab Inc | 皮膚外用剤 |
JP2003206224A (ja) * | 2002-01-08 | 2003-07-22 | Otsuka Pharmaceut Co Ltd | 外用組成物 |
JP4349809B2 (ja) * | 2003-01-17 | 2009-10-21 | 株式会社林原生物化学研究所 | コラーゲン生成促進剤 |
US20040146539A1 (en) * | 2003-01-24 | 2004-07-29 | Gupta Shyam K. | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits |
EP1652527A4 (en) * | 2003-07-18 | 2012-03-14 | Hayashibara Biochem Lab | MINERAL ABSORBENT AND ITS USE |
US20070129430A1 (en) * | 2003-10-07 | 2007-06-07 | Satomi Miyata | Agent for enhancing the production of collagen, their preparation and use |
-
2006
- 2006-08-03 CN CNA2006800281988A patent/CN101232891A/zh active Pending
- 2006-08-03 CN CN201110180313.6A patent/CN102266274B/zh active Active
- 2006-08-03 EP EP06782270A patent/EP1932530A4/en not_active Withdrawn
- 2006-08-03 WO PCT/JP2006/315410 patent/WO2007018124A1/ja active Application Filing
- 2006-08-03 JP JP2007529534A patent/JP5106109B2/ja active Active
- 2006-08-03 US US12/063,563 patent/US20090110671A1/en not_active Abandoned
-
2008
- 2008-01-22 KR KR1020087001705A patent/KR101342192B1/ko active IP Right Grant
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07143876A (ja) | 1992-12-28 | 1995-06-06 | Hayashibara Biochem Lab Inc | 非還元性糖質生成酵素とその製造方法並びに用途 |
JPH07213283A (ja) | 1993-06-03 | 1995-08-15 | Hayashibara Biochem Lab Inc | トレハロース遊離酵素とその製造方法並びに用途 |
JPH10203952A (ja) | 1997-01-17 | 1998-08-04 | Shiseido Co Ltd | コラーゲン産生促進剤 |
JP2000228980A (ja) | 1998-09-11 | 2000-08-22 | Hayashibara Biochem Lab Inc | 非還元性糖質生成酵素及びトレハロース遊離酵素ならびに該酵素を用いる糖質の製造方法 |
JP2000159656A (ja) * | 1998-12-01 | 2000-06-13 | Taiyo Kagaku Co Ltd | コラーゲン合成促進剤 |
JP2001048789A (ja) * | 1999-08-09 | 2001-02-20 | Yaizu Suisankagaku Industry Co Ltd | 美肌促進剤及び美容健康食品 |
WO2001060388A1 (fr) | 2000-02-15 | 2001-08-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Activateur de cellules |
WO2002010361A1 (fr) | 2000-08-01 | 2002-02-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Synthase d'$g(a)-isomaltosylglucosaccharide, procede de preparation et utilisation associes |
JP2003171290A (ja) | 2001-09-27 | 2003-06-17 | Hayashibara Biochem Lab Inc | コラーゲン産生増強剤の製造方法とその用途 |
JP2004107243A (ja) * | 2002-09-17 | 2004-04-08 | Fancl Corp | シワ及び/又はたるみ改善用キット |
JP2004174880A (ja) | 2002-11-27 | 2004-06-24 | Toppan Printing Co Ltd | 潜像を有する画像形成体およびその顕像化方法 |
WO2004056216A1 (ja) | 2002-12-19 | 2004-07-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 組成物における水分の変動を抑制する方法とその用途 |
WO2004071472A1 (ja) * | 2003-02-13 | 2004-08-26 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α,α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤 |
JP2005095148A (ja) | 2003-08-28 | 2005-04-14 | Hayashibara Biochem Lab Inc | 環状マルトシルマルトース及び環状マルトシルマルトース生成酵素とそれらの製造方法並びに用途 |
Non-Patent Citations (3)
Title |
---|
BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 68, no. 4, 2004, pages 767 - 773 |
HAN D. C., JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. 9, 1999, pages 1 |
See also references of EP1932530A4 |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11045490B2 (en) | 2003-04-10 | 2021-06-29 | Allergan Industrie, Sas | Injectable monophase hydrogels |
US10080767B2 (en) | 2003-04-10 | 2018-09-25 | Allergan Industrie Sas | Injectable monophase hydrogels |
US9062130B2 (en) | 2003-04-10 | 2015-06-23 | Allergan Industrie Sas | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
US10653716B2 (en) | 2003-04-10 | 2020-05-19 | Allergan Industrie, Sas | Injectable monophase hydrogels |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
JP5551582B2 (ja) * | 2008-03-17 | 2014-07-16 | 株式会社林原 | 皮膚外用剤 |
JPWO2009116450A1 (ja) * | 2008-03-17 | 2011-07-21 | 株式会社林原生物化学研究所 | エラスターゼ活性阻害剤 |
US10391202B2 (en) | 2008-08-04 | 2019-08-27 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10328180B2 (en) | 2008-08-04 | 2019-06-25 | Allergan Industrie, S.A.S. | Hyaluronic acid-based gels including lidocaine |
US11020512B2 (en) | 2008-08-04 | 2021-06-01 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US10485896B2 (en) | 2008-08-04 | 2019-11-26 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9358322B2 (en) | 2008-08-04 | 2016-06-07 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US11173232B2 (en) | 2008-08-04 | 2021-11-16 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9089517B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9089519B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9238013B2 (en) | 2008-08-04 | 2016-01-19 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9089518B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9855367B2 (en) | 2010-01-13 | 2018-01-02 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US10806821B2 (en) | 2010-01-13 | 2020-10-20 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US20110171286A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
US20120225842A1 (en) * | 2010-01-13 | 2012-09-06 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
US9333160B2 (en) | 2010-01-13 | 2016-05-10 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US10449268B2 (en) | 2010-01-13 | 2019-10-22 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
US10220113B2 (en) | 2010-01-13 | 2019-03-05 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9655991B2 (en) | 2010-01-13 | 2017-05-23 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
US8946192B2 (en) * | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9125840B2 (en) | 2010-03-12 | 2015-09-08 | Allergan Industrie Sas | Methods for improving skin conditions |
US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US9585821B2 (en) | 2010-03-12 | 2017-03-07 | Allergan Industrie Sas | Methods for making compositions for improving skin conditions |
US10111984B2 (en) | 2010-03-22 | 2018-10-30 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US10905797B2 (en) | 2010-03-22 | 2021-02-02 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9480775B2 (en) | 2010-03-22 | 2016-11-01 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9012517B2 (en) | 2010-03-22 | 2015-04-21 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
JP2019069238A (ja) * | 2011-06-03 | 2019-05-09 | アラーガン、インコーポレイテッドAllergan,Incorporated | 抗酸化物質を含む皮膚充填剤組成物 |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
JP6995946B2 (ja) | 2011-06-03 | 2022-01-17 | アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエ | 抗酸化物質を含む皮膚充填剤組成物 |
KR20190100979A (ko) * | 2011-06-03 | 2019-08-29 | 알러간, 인코포레이티드 | 항산화제를 포함하는 피부 충전제 조성물 |
US9737633B2 (en) | 2011-06-03 | 2017-08-22 | Allergan, Inc. | Dermal filler compositions including antioxidants |
KR102015676B1 (ko) | 2011-06-03 | 2019-10-21 | 알러간, 인코포레이티드 | 항산화제를 포함하는 피부 충전제 조성물 |
US9962464B2 (en) | 2011-06-03 | 2018-05-08 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9950092B2 (en) | 2011-06-03 | 2018-04-24 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US10624988B2 (en) | 2011-06-03 | 2020-04-21 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
JP2017008097A (ja) * | 2011-06-03 | 2017-01-12 | アラーガン、インコーポレイテッドAllergan,Incorporated | 抗酸化物質を含む皮膚充填剤組成物 |
KR20140072008A (ko) * | 2011-06-03 | 2014-06-12 | 알러간, 인코포레이티드 | 항산화제를 포함하는 피부 충전제 조성물 |
KR102154944B1 (ko) | 2011-06-03 | 2020-09-11 | 알러간 인더스트리 에스에이에스 | 항산화제를 포함하는 피부 충전제 조성물 |
KR20200106224A (ko) * | 2011-06-03 | 2020-09-11 | 알러간 인더스트리 에스에이에스 | 항산화제를 포함하는 피부 충전제 조성물 |
JP2017217500A (ja) * | 2011-06-03 | 2017-12-14 | アラーガン、インコーポレイテッドAllergan,Incorporated | 抗酸化物質を含む皮膚充填剤組成物 |
JP2020179280A (ja) * | 2011-06-03 | 2020-11-05 | アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエAllergan Industrie Sas | 抗酸化物質を含む皮膚充填剤組成物 |
KR102312056B1 (ko) | 2011-06-03 | 2021-10-12 | 알러간 인더스트리 에스에이에스 | 항산화제를 포함하는 피부 충전제 조성물 |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
KR102238406B1 (ko) | 2011-06-03 | 2021-04-08 | 알러간 인더스트리 에스에이에스 | 항산화제를 포함하는 피부 충전제 조성물 |
KR20210040466A (ko) * | 2011-06-03 | 2021-04-13 | 알러간 인더스트리 에스에이에스 | 항산화제를 포함하는 피부 충전제 조성물 |
US10994049B2 (en) | 2011-06-03 | 2021-05-04 | Allergan Industrie, Sas | Dermal filler compositions for fine line treatment |
US11000626B2 (en) | 2011-06-03 | 2021-05-11 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
JP2014515307A (ja) * | 2011-06-03 | 2014-06-30 | アラーガン、インコーポレイテッド | 抗酸化物質を含む皮膚充填剤組成物 |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9821086B2 (en) | 2011-09-06 | 2017-11-21 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10434214B2 (en) | 2011-09-06 | 2019-10-08 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US11833269B2 (en) | 2011-09-06 | 2023-12-05 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
JP2015151379A (ja) * | 2014-02-18 | 2015-08-24 | 株式会社ノエビア | 水性クレンジング料 |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US11260015B2 (en) | 2015-02-09 | 2022-03-01 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
US12011500B2 (en) | 2015-02-09 | 2024-06-18 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
WO2020226147A1 (ja) * | 2019-05-07 | 2020-11-12 | 株式会社林原 | ゲル状皮膚外用組成物 |
KR20230143550A (ko) * | 2022-04-05 | 2023-10-12 | (주)뉴트리 | 저장 안정성이 향상된 콜라겐 조성물 및 이의 제조방법 |
KR102629510B1 (ko) * | 2022-04-05 | 2024-01-25 | (주)뉴트리 | 저장 안정성이 향상된 콜라겐 조성물 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR101342192B1 (ko) | 2013-12-16 |
US20090110671A1 (en) | 2009-04-30 |
KR20080034890A (ko) | 2008-04-22 |
EP1932530A4 (en) | 2009-04-29 |
CN102266274A (zh) | 2011-12-07 |
CN102266274B (zh) | 2016-05-18 |
CN101232891A (zh) | 2008-07-30 |
EP1932530A1 (en) | 2008-06-18 |
JP5106109B2 (ja) | 2012-12-26 |
JPWO2007018124A1 (ja) | 2009-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5106109B2 (ja) | コラーゲン産生増強剤とその用途 | |
JP5654731B2 (ja) | 藍草抽出物粉末とその製造方法及びその藍草抽出物粉末の用途 | |
EP1930012B1 (en) | Cellooligosaccharide-containing composition | |
JP5050350B2 (ja) | コラーゲン産生増強剤とその製造方法並びに用途 | |
JP4754066B2 (ja) | 抗関節障害剤 | |
JP5479891B2 (ja) | 新規ローヤルゼリー分画物とその製造方法並びに用途 | |
JP4456796B2 (ja) | コラーゲン産生増強剤の製造方法とその用途 | |
JP2001048789A (ja) | 美肌促進剤及び美容健康食品 | |
KR101096393B1 (ko) | 보습용 화장료 조성물 | |
JP2006316053A (ja) | 細胞障害抑制剤とその用途 | |
ES2735991T3 (es) | Composición antioxidante | |
JP6235779B2 (ja) | 葉酸含有組成物及び葉酸の安定化方法 | |
JP2000344622A (ja) | スチルベン系化合物及びそれを含有する植物抽出物の安定化およびスチルベン系化合物及びそれを含有する植物抽出物を安定配合した食品、医薬品、化粧品、口腔製剤 | |
US20140005139A1 (en) | Cellooligosaccharide-containing composition | |
TWI301836B (en) | Crystalline α-d-glucosyl α-d-galactoside, saccharide composition comprising the same, process for producing the same, and uses thereof | |
JP2003226632A (ja) | 皮膚化粧料及び美容用飲食品 | |
WO2005079825A1 (ja) | クランベリー抽出物を有効成分とする経口用皮膚改善剤 | |
TW470749B (en) | Propolis extract with improved water-solubility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680028198.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020087001705 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2007529534 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12063563 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006782270 Country of ref document: EP |